.@chaidiscovery raised a Series B just three months after their Series A, and we co-led it. GC's Elena Viboch recently joined @Bloomberg's @CarolineHydeTV alongside Chai Discovery co-founder @joshim5 to discuss our life sciences investment strategy and the breakthrough technology behind Chai Discovery. We believe 2026 will be the year of deployment for AI in pharma. Chai Discovery’s latest model, Chai-2, has achieved an 85% success rate in computationally designing molecules that meet drug-like properties. In our view, pharmaceutical companies that adopt this technology will leapfrog those who do not. We partner with companies like Chai Discovery to turn known biology and impossible chemistry into lifesaving treatments. Why we invested → More on our life sciences thesis →